Rani Therapeutics Holdings Inc
Change company Symbol lookup
Select an option...
RANI Rani Therapeutics Holdings Inc
SASOF Sasol Ltd
SMBC Southern Missouri Bancorp Inc
ALG Alamo Group Inc
AFFCF American Future Fuel Corp
TDS-U Telephone and Data Systems Inc
FRSH Freshworks Inc
TA Travelcenters of America Inc
WWW Wolverine World Wide Inc
$PABEZ5T Bloomberg PAB Eurozone 50 Decrement
Go

Health Care : Pharmaceuticals | Small Cap Growth
Company profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The Company manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.

Closing Price
$8.28
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Above Average)
Volume:
65,333

10-day average volume:
58,198
65,333

Company Profile

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The Company manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
--
Price/Book (MRQ)
9.49x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
338.9K
Previous Month
420.9K
Percent of Float
3.36%
Days to Cover
8.6156 Days

Share Information

RANI is in a share class of common stock
Float
10.1M
Shares Outstanding
49.4M
Institutions Holding Shares
40
11.44%

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Mir ImranPres.
  • Talat ImranCEO
  • Svai S. SanfordCFO
  • Mir HashimCSO
  • Eric GroenCounsel

Address

Insider Trading

During the most recent quarter, 139K shares were bought, and 161K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.